Edgardo Ortiz Flores, MD
Hematology & Oncology · Brunswick, MENPI 1184933996
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,932 of the $2,262 with a category attached, or 85.4%. It is spread thinly across 33 manufacturers, the largest accounting for just 8.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,080 and has fallen 98.7% since, to $27 in 2025.
Across 110 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$186
- Incyte Corporation$185
- Novartis$179
- Astellas Pharma US Inc$166
- Genentech USA, Inc.$149
- Takeda Pharmaceuticals U.S.A., Inc.$146
- plus $1K from 27 others
Across 8 payments — averaging $5350.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$18K
- Merck$18K
- Novocure Inc.$7K
What the payments were for
- Food & beverage$1,93285%
- Education$33015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 15 | $186 |
| Incyte Corporation | 8 | $185 |
| Novartis | 12 | $179 |
| Astellas Pharma US Inc | 5 | $166 |
| Genentech USA, Inc. | 4 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $146 |
| Merck | 6 | $109 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $104 |
| Bayer | 5 | $93 |
| Dendreon Pharmaceuticals LLC | 3 | $90 |
| Tersera Therapeutics LLC | 4 | $87 |
| Amgen | 3 | $86 |
| Gilead | 3 | $76 |
| Boehringer Ingelheim | 4 | $61 |
| AbbVie | 2 | $61 |
| AstraZeneca | 2 | $55 |
| Array Biopharma Inc | 2 | $44 |
| Pfizer | 3 | $42 |
| EMD Serono, Inc. | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Bristol Myers Squibb | 2 | $34 |
| Janssen Scientific Affairs, LLC | 1 | $29 |
| Verastem, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $25 |
| Aurobindo Pharma USA, Inc. | 1 | $24 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Secura Bio, Inc. | 1 | $19 |
| Exelixis Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Advanced Accelerator Applications | 1 | $12 |
How this compares
$2,262 in reported general payments places this provider in the 65th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 73 | $1,074 |
| Hydroxyurea | 14 | $386 |
| Tamoxifen Citrate | 12 | $298 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Brunswick
- Madelaine SgroiBrunswick$3K
- Helen YuanBrunswick$1K
- Hillary GlickBrunswick$215
- Allison SmithBrunswick$215
- Matthew DuganWestbrook$577K
- John WintersWestbrook$341K
- Helen RyanKennebunk$83K
- Eleni NackosWestbrook$79K
- Christian ThomasWestbrook$54K
- Devon EvansWestbrook$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.